The Latin America, Middle East and Africa Newborn Screening Market is expected to witness market growth of 8.4% CAGR during the forecast period (2022-2028).
Newborn screening is a set of tests performed on one- to two-day-old babies, usually before they leave the hospital that includes blood, hearing, and heart screening. This is done to see if there are any major health problems that don't show symptoms at birth. Newborn babies with health problems may not show any signs until later in life. Newborn screening aids in the early diagnosis of these illnesses so that babies can start treatment as soon as possible before the disease becomes serious or so that early interventions can be implemented.
Increased government assistance for newborn screening and advancements in screening technology are two major driving factors for the Newborn Screening Industry. Furthermore, due to the high birth rate and rising incidence of neonatal disorder, the newborn screening market is predicted to rise. Conversely, due to rising birth rates and disposable income in emerging markets such as Brazil, China, and India, genetic disease screening and emerging markets such as Brazil, China, and India give considerable potential to key participants in this industry.
The technology makes it easier to understand crucial biostatistical data such as infants, fertility, mortality, and marriage and divorce rates. There were 29,282 infants in 2014, with a monthly rate of 2,440, implying that there are 81 newborns every day, or 3-4 newborns every hour. According to Al Muhairi, the overall number of newborns in Dubai climbed by 19.1 percent from 24,583 in 2009 to 29,282 in 2014.
The Brazil market dominated the LAMEA Newborn Screening Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $28 Million by 2028. The Argentina market is expected to showcase a CAGR of 9% during (2022-2028). Additionally, The UAE market is estimated to grow at a CAGR of 8.1% during (2022-2028).
Based on Product Type, the market is segmented into Consumables and Instrument. Based on Test Type, the market is segmented into Blood Test, Hearing Screening Test, and Heart screening. Based on End User, the market is segmented into Hospitals and Clinical Laboratories. Based on Technology, the market is segmented into Tandem Mass Spectrometry (TMS), Molecular Assays, Immunoassays & Enzymatic Assays, Hearing Screen Technology, Pulse Oximetry Screening Technology, Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Natus Medical Incorporated, Masimo Corporation, Waters Corporation, PerkinElmer, Inc., AB Sciex LLC (Danaher Corporation), Medtronic PLC (Covidien plc), Trivitron Healthcare Pvt. Ltd.
By Product Type
Newborn screening is a set of tests performed on one- to two-day-old babies, usually before they leave the hospital that includes blood, hearing, and heart screening. This is done to see if there are any major health problems that don't show symptoms at birth. Newborn babies with health problems may not show any signs until later in life. Newborn screening aids in the early diagnosis of these illnesses so that babies can start treatment as soon as possible before the disease becomes serious or so that early interventions can be implemented.
Increased government assistance for newborn screening and advancements in screening technology are two major driving factors for the Newborn Screening Industry. Furthermore, due to the high birth rate and rising incidence of neonatal disorder, the newborn screening market is predicted to rise. Conversely, due to rising birth rates and disposable income in emerging markets such as Brazil, China, and India, genetic disease screening and emerging markets such as Brazil, China, and India give considerable potential to key participants in this industry.
The technology makes it easier to understand crucial biostatistical data such as infants, fertility, mortality, and marriage and divorce rates. There were 29,282 infants in 2014, with a monthly rate of 2,440, implying that there are 81 newborns every day, or 3-4 newborns every hour. According to Al Muhairi, the overall number of newborns in Dubai climbed by 19.1 percent from 24,583 in 2009 to 29,282 in 2014.
The Brazil market dominated the LAMEA Newborn Screening Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $28 Million by 2028. The Argentina market is expected to showcase a CAGR of 9% during (2022-2028). Additionally, The UAE market is estimated to grow at a CAGR of 8.1% during (2022-2028).
Based on Product Type, the market is segmented into Consumables and Instrument. Based on Test Type, the market is segmented into Blood Test, Hearing Screening Test, and Heart screening. Based on End User, the market is segmented into Hospitals and Clinical Laboratories. Based on Technology, the market is segmented into Tandem Mass Spectrometry (TMS), Molecular Assays, Immunoassays & Enzymatic Assays, Hearing Screen Technology, Pulse Oximetry Screening Technology, Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Natus Medical Incorporated, Masimo Corporation, Waters Corporation, PerkinElmer, Inc., AB Sciex LLC (Danaher Corporation), Medtronic PLC (Covidien plc), Trivitron Healthcare Pvt. Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Product Type
- Consumables
- Instrument
- Blood Test
- Hearing Screening Test
- Heart screening
- Hospitals
- Clinical Laboratories
- Tandem Mass Spectrometry (TMS)
- Molecular Assays
- Immunoassays & Enzymatic Assays
- Hearing Screen Technology
- Pulse Oximetry Screening Technology
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- General Electric (GE) Co. (GE Healthcare)
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories, Inc.
- Natus Medical Incorporated
- Masimo Corporation
- Waters Corporation
- PerkinElmer, Inc.
- AB Sciex LLC (Danaher Corporation)
- Medtronic PLC (Covidien plc)
- Trivitron Healthcare Pvt. Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Newborn Screening Market by Product Type
Chapter 5. LAMEA Newborn Screening Market by Test Type
Chapter 6. LAMEA Newborn Screening Market by End User
Chapter 7. LAMEA Newborn Screening Market by Technology
Chapter 8. LAMEA Newborn Screening Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- General Electric (GE) Co. (GE Healthcare)
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories, Inc.
- Natus Medical Incorporated
- Masimo Corporation
- Waters Corporation
- PerkinElmer, Inc.
- AB Sciex LLC (Danaher Corporation)
- Medtronic PLC (Covidien plc)
- Trivitron Healthcare Pvt. Ltd.
Methodology
LOADING...
